AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
furazolidone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1257 | 67-45-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.04 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,STK33,SYK,TEK,TTK | 41 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,DDR1,DYRK1B,GRK2,GSK3B,IRAK1,MAP2K6,MAP3K14,MAPK1,MAPK7,MARK4,MET,PRKDC,STK33,SYK,TEK,TTK,UHMK1 | 20 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 1958 | FDA | SHIRE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Appendicolith | 358.12 | 222.49 | 118 | 6671 | 13338 | 42601208 |
| Blood phosphorus increased | 346.06 | 222.49 | 113 | 6676 | 12412 | 42602134 |
| Myasthenia gravis | 325.61 | 222.49 | 115 | 6674 | 16022 | 42598524 |
| Appendicitis | 319.75 | 222.49 | 121 | 6668 | 20492 | 42594054 |
| Hyperphosphataemia | 274.99 | 222.49 | 96 | 6693 | 12908 | 42601638 |
| Ventricular fibrillation | 265.64 | 222.49 | 118 | 6671 | 30005 | 42584541 |
| Stress | 254.26 | 222.49 | 129 | 6660 | 44083 | 42570463 |
| Analgesic therapy | 234.56 | 222.49 | 72 | 6717 | 6452 | 42608094 |
| Cardiogenic shock | 234.52 | 222.49 | 114 | 6675 | 35526 | 42579020 |
| Blood uric acid increased | 229.22 | 222.49 | 88 | 6701 | 15459 | 42599087 |
| Hypophosphataemia | 227.12 | 222.49 | 95 | 6694 | 20850 | 42593696 |
| Sleep disorder therapy | 226.46 | 222.49 | 71 | 6718 | 6823 | 42607723 |
| Drug therapy | 223.40 | 222.49 | 69 | 6720 | 6311 | 42608235 |
| Incorrect route of product administration | 223.20 | 222.49 | 98 | 6691 | 24207 | 42590339 |
| Bacterial infection | 222.83 | 222.49 | 102 | 6687 | 27777 | 42586769 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Appendicolith | 485.07 | 172.00 | 125 | 7357 | 14130 | 110567687 |
| Blood phosphorus increased | 444.52 | 172.00 | 120 | 7362 | 16220 | 110565597 |
| Myasthenia gravis | 420.74 | 172.00 | 122 | 7360 | 21389 | 110560428 |
| Appendicitis | 412.17 | 172.00 | 128 | 7354 | 28336 | 110553481 |
| Hyperphosphataemia | 365.59 | 172.00 | 103 | 7379 | 16278 | 110565539 |
| Ventricular fibrillation | 353.86 | 172.00 | 125 | 7357 | 41188 | 110540629 |
| Analgesic therapy | 323.00 | 172.00 | 79 | 7403 | 7205 | 110574612 |
| Sleep disorder therapy | 315.95 | 172.00 | 78 | 7404 | 7393 | 110574424 |
| Drug therapy | 307.72 | 172.00 | 76 | 7406 | 7215 | 110574602 |
| Blood uric acid increased | 303.94 | 172.00 | 95 | 7387 | 21434 | 110560383 |
| Cardiogenic shock | 300.06 | 172.00 | 121 | 7361 | 57217 | 110524600 |
| Hypophosphataemia | 290.18 | 172.00 | 102 | 7380 | 33080 | 110548737 |
| Bacterial infection | 282.39 | 172.00 | 109 | 7373 | 45927 | 110535890 |
| Stress | 273.27 | 172.00 | 136 | 7346 | 105212 | 110476605 |
| Ascites | 265.17 | 172.00 | 128 | 7354 | 92680 | 110489137 |
| Neuralgia | 262.92 | 172.00 | 105 | 7377 | 48373 | 110533444 |
| Multiple organ dysfunction syndrome | 239.85 | 172.00 | 141 | 7341 | 151569 | 110430248 |
| Incorrect route of product administration | 231.50 | 172.00 | 104 | 7378 | 63957 | 110517860 |
| Antacid therapy | 230.56 | 172.00 | 57 | 7425 | 5427 | 110576390 |
| Anticoagulant therapy | 216.73 | 172.00 | 54 | 7428 | 5307 | 110576510 |
| Activated partial thromboplastin time prolonged | 211.82 | 172.00 | 73 | 7409 | 22295 | 110559522 |
| Diabetes mellitus | 207.69 | 172.00 | 111 | 7371 | 99270 | 110482547 |
| Iron deficiency | 205.30 | 172.00 | 68 | 7414 | 18408 | 110563409 |
| Abdominal distension | 196.61 | 172.00 | 131 | 7351 | 174972 | 110406845 |
| Thrombosis | 192.96 | 172.00 | 109 | 7373 | 108553 | 110473264 |
| Hyponatraemia | 191.07 | 172.00 | 140 | 7342 | 217513 | 110364304 |
| End stage renal disease | 187.60 | 172.00 | 66 | 7416 | 21407 | 110560410 |
| Chronic obstructive pulmonary disease | 179.08 | 172.00 | 104 | 7378 | 109054 | 110472763 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G01AX06 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Other antiinfectives and antiseptics |
| ATC | P01AB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Nitroimidazole derivatives |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D000994 | Antitrichomonal Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:38623 | EC 1.4.3.4 (monoamine oxidase) inhibitor |
| CHEBI has role | CHEBI:50685 | antitrichomonal drug |
Related Drugs by ATC class:
G01AX Other antiinfectives and antiseptics 10 drugs
P01AB Nitroimidazole derivatives 7 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Dogs | Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and pyogenic dermatitis | Indication |
| Horses | Prevention of bacterial infection of superficial wounds, abrasions, lacerations, and following firing (heat or electrocautery) | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Furox Aerosol Powder, Topazone Aerosol Powder | Kinetic Technologies LLC | 1 |
| Furall | Farnam Companies Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.72 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018877 | VUID |
| N0000147172 | NUI |
| D00830 | KEGG_DRUG |
| 4018877 | VANDF |
| C0016855 | UMLSCUI |
| CHEBI:5195 | CHEBI |
| FUR | PDB_CHEM_ID |
| CHEMBL1103 | ChEMBL_ID |
| DB00614 | DRUGBANK_ID |
| D005664 | MESH_DESCRIPTOR_UI |
| 5323714 | PUBCHEM_CID |
| 12343 | IUPHAR_LIGAND_ID |
| 273 | INN_ID |
| 5J9CPU3RE0 | UNII |
| 224944 | RXNORM |
| 416 | MMSL |
| 4768 | MMSL |
| d00243 | MMSL |
| 002855 | NDDF |
| 416556006 | SNOMEDCT_US |
| 91314000 | SNOMEDCT_US |
Pharmaceutical products:
None